PFOA, PFHxA and C6O4 differently modulate the expression of CXCL8 in normal thyroid cells and in thyroid cancer cell lines - Environmental Science and Pollution Research
Source : https://link.springer.com/article/10.1007/s11356-023-26797-6
Industrial chemical PFAS are persistent pollutants. Long chain PFAS were taken out of production due to their risk for human health, however, new congeners PFAS have been introduced.
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1115405/full
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET and NTRK gene fusions.
Conclusions: We found that ERBB fusions are recurrent mutations that occur across multiple cancer types. We also establish that adapter-tethered and kinase-tethered fusions are oncogenic and can be inhibited with EGFR or HER2 inhibitors. We further propose a nomenclature system to categorize these fusions into several functional classes.
Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis
Source : https://academic.oup.com/bjsopen/article/7/3/zrad029/7153160?login=false
Differentiated thyroid carcinoma (DTC) is a tumour with a high incidence. From 1975 to 2014, the annual incidence increased from 4.9 to 14.3 patients per 100 000 population in the...
Conclusions: Papillary thyroid carcinoma with concomitant BRAF-V600E and TERT promoter mutations demonstrated an aggressive course of disease, suggesting the need for a more extensive surgical strategy. RET rearrangement-positive papillary thyroid carcinoma did not affect the clinical outcome, potentially obviating the need for prophylactic...
Progress and challenges in RET-targeted cancer therapy - Frontiers of Medicine
Source : https://link.springer.com/article/10.1007/s11684-023-0985-y
The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer,...
Conclusions/Relevance: Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better...
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37141396/
Triple-negative breast cancers (TNBC) represent a pathological subtype of breast cancer, which are characterized by strong invasiveness, high metastasis rate, low survival rate, and poor prognosis, especially in patients who...
Conclusions/Relevance: This case report is believed to be the first demonstrating clinical efficacy of pralsetinib in a patient with multidrug-resistant breast cancer with a coiled-coil domain-containing protein 6-rearranged during transfection mutation.